Researchers found leukemias trending higher as the ‘baby boomer’ generation ages. Interestingly, incidence of all cancers was not correlated with the increase in older Americans.
An Eastern Cooperative Oncology Group (ECOG) performance status of ≥2 is linked to lower treatment satisfaction in patients with relapsed or refractory multiple myeloma (RRMM), but receiving medication orally is linked to higher satisfaction.
A tumor-initiating cell marker was identified in multiple myeloma cell lines and patient samples; evidence suggests the marker may have therapeutic potential.
The FDA has approved Inrebic (fedratinib; Celgene) capsules to treat adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.
Although statistically insignificant, results of a randomized study determined the potential for nurse-led interventions as adjunct posttreatment care for lymphoma survivors.
No data are available from randomized clinical trials comparing ibrutinib monotherapy with rituximab-based chemoimmunotherapy in Waldentrom Macroglobulinemia.
Researchers reported follow-up data for patients with advanced-stage Hodgkin lymphoma evaluated for response with positron emission tomography scanning.
Two randomized phase 3 trials investigating the safety and efficacy of adding pembrolizumab to standard-of-care therapies for multiple myeloma were halted due to poor outcomes in their respective intervention arms.
A considerable proportion of patients with Waldenström macroglobulinemia experience disease-related adverse events, such as hyperviscosity and neuropathy.
Fiscal year 2020 Inpatient Prospective Payment System from CMS includes an increase in the reimbursement rate for CAR-T therapy; however, it falls short of suggestions ASH had submitted to the agency.
